Your browser doesn't support javascript.
loading
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis.
Cainap, Calin; Ungur, Rodica Ana; Bochis, Ovidiu-Vasile; Achimas, Patriciu; Vlad, Catalin; Havasi, Andrei; Vidrean, Andreea; Farcas, Anca; Tat, Tiberiu; Gherman, Alexandra; Piciu, Andra; Bota, Madalina; Constantin, Anne-Marie; Pop, Laura Ancuta; Maniu, Dana; Crisan, Ovidiu; Cioban, Cosmin Vasile; Balacescu, Ovidiu; Coza, Ovidiu; Balacescu, Loredana; Marta, Monica Mihaela; Dronca, Eleonora; Cainap, Simona.
Afiliação
  • Cainap C; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Ungur RA; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Bochis OV; Department of Medical Specialties, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Achimas P; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Vlad C; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Havasi A; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Vidrean A; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Farcas A; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Tat T; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Gherman A; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Piciu A; Department of Medical Specialties, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Bota M; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Constantin AM; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Pop LA; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Maniu D; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Crisan O; Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Cioban CV; Department of Mother and Child, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Balacescu O; Department of Morphological Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Coza O; Department of Molecular Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Balacescu L; Faculty of Physics, Babes-Bolyai University, Cluj-Napoca, Romania.
  • Marta MM; Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Dronca E; Faculty of Dental Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Cainap S; Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
PLoS One ; 16(4): e0248922, 2021.
Article em En | MEDLINE | ID: mdl-33909622
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Irinotecano / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Romênia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Irinotecano / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Romênia